Noseda, Roberta; Müller, Laura; Bedussi, Francesca; Fusaroli, Michele; Raschi, Emanuel; Ceschi, Alessandro, Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System, «CANCERS», 2022, 15, Article number: 173, pp. 1 - 14 [articolo]Open Access
Fusaroli M.; Raschi E.; Giunchi V.; Menchetti M.; Rimondini Giorgini R.; De Ponti F.; Poluzzi E., Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System, «INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY», 2022, 25, pp. 727 - 736 [articolo]Open Access
Raschi, Emanuel; Fusaroli, Michele; Gatti, Milo; Caraceni, Paolo; Poluzzi, Elisabetta; De Ponti, Fabrizio, Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal, «PHARMACEUTICALS», 2022, 15, Article number: 645, pp. 1 - 11 [articolo]Open Access
Giunchi, V; Fusaroli, M; Lunghi, C; Zongo, A; Raschi, E; Poluzzi, E, Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system, «PHARMACOEPIDEMIOLOGY AND DRUG SAFETY», 2022, 31, pp. 222 - 223 [abstract]
Fusaroli M.; Isgro V.; Cutroneo P.M.; Ferrajolo C.; Cirillo V.; Del Bufalo F.; Raschi E.; Poluzzi E.; Trifiro G., Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database, «DRUG SAFETY», 2022, 45, pp. 891 - 908 [articolo]Open Access
Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco, Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2022, 17, pp. 43 - 51 [articolo]Open Access
Antonazzo I.C.; Lombardi N.; Fusaroli M.; Battini V.; Convertino I.; Crisafulli S., Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology, «EPIDEMIOLOGIA E PREVENZIONE», 2022, 46, pp. 217 - 218 [articolo]
Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F., Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System, «AMERICAN JOURNAL OF CLINICAL DERMATOLOGY», 2022, 23, pp. 247 - 255 [articolo]
Lunghi C.; Trevisan C.; Fusaroli M.; Giunchi V.; Raschi E.; Sangiorgi E.; Domenicali M.; Volpato S.; De Ponti F.; Poluzzi E., Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People, «PHARMACEUTICALS», 2022, 15, Article number: 977, pp. 1 - 15 [articolo]Open Access
Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [articolo]Open Access
Khouri, Charles; Fusaroli, Michele; Salvo, Francesco; Raschi, Emanuel, Transparency and robustness of safety signals, «BMJ», 2022, 379, pp. 2588 - 2588 [replica/breve intervento]
Lunghi, C; Fusaroli, M; Giunchi, V; Raschi, E; Zongo, A; Poluzzi, E, What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System, «DRUG SAFETY», 2022, 45, pp. 1242 - 1243 [abstract]
Raschi, Emanuel; Fusaroli, Michele; Diemberger, Igor; Poluzzi, Elisabetta, Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”, «DRUG SAFETY», 2021, 44, pp. 505 - 506 [replica/breve intervento]
Filippini D.M.; Gatti M.; Di Martino V.; Cavalieri S.; Fusaroli M.; Ardizzoni A.; Raschi E.; Licitra L., Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, «INTERNATIONAL JOURNAL OF CANCER», 2021, 149, pp. 675 - 683 [articolo]Open Access
Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]Open Access
